Open Access
27.04.2023 | Original Research Article
Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial
verfasst von:
Steven C. R. Williams, Ndaba Mazibuko, Owen O’Daly, Christian Zurth, Fiona Patrick, Christian Kappeler, Iris Kuss, Patricia E. Cole
Off-target central nervous system (CNS) effects are associated with androgen receptor (AR)-targeting treatments for prostate cancer. Darolutamide is a structurally distinct AR inhibitor with low blood–brain barrier penetration.
Objective
We compared cerebral blood flow (CBF) in grey matter and specific regions related to cognition after darolutamide, enzalutamide, or placebo administration, using arterial spin-label magnetic resonance imaging (ASL-MRI).
Methods
This phase I, randomized, placebo-controlled, three-period crossover study administered single doses of darolutamide, enzalutamide, or placebo to 23 healthy males (aged 18–45 years) at 6-week intervals. ASL-MRI mapped CBF 4 h post-treatment. Treatments were compared using paired t-tests.
Results
Drug concentrations during scans confirmed similar unbound exposure of darolutamide and enzalutamide, with complete washout between treatments. A significant localized 5.2% (p = 0.01) and 5.9% (p < 0.001) CBF reduction in the temporo-occipital cortices was observed for enzalutamide versus placebo and versus darolutamide, respectively, with no significant differences for darolutamide versus placebo. Enzalutamide reduced CBF in all prespecified regions, with significant reductions versus placebo (3.9%, p = 0.045) and versus darolutamide (4.4%, p = 0.037) in the left and right dorsolateral prefrontal cortices, respectively. Darolutamide showed minimal changes in CBF versus placebo in cognition-relevant regions.
Conclusions
Darolutamide did not significantly alter CBF, consistent with its low blood–brain barrier penetration and low risk of CNS-related adverse events. A significant reduction in CBF was observed with enzalutamide. These results may be relevant to cognitive function with early and extended use of second-generation AR inhibitors, and warrant further investigation in patients with prostate cancer.
Trial Registration Number
NCT03704519; date of registration: October 2018.
Key Points
This study evaluated the effect of darolutamide and enzalutamide on cerebral blood flow measured by arterial spin-labeled magnetic resonance imaging as a surrogate measure of the drugs’ brain penetration.
Consistent with low blood–brain barrier penetration, darolutamide showed no significant reduction in cerebral blood flow compared with placebo.
In contrast, enzalutamide significantly reduced localized cerebral blood flow in all prespecified regions.
1 Introduction
Androgen deprivation therapy (ADT) is the backbone of systemic therapy for prostate cancer; however, a range of cognitive and other central nervous system (CNS) changes have been associated with ADT [1, 2]. In clinical studies, CNS-related adverse events (AEs) such as seizures, dizziness, fatigue, falls, and impaired cognitive function have been reported with ADT as well as novel androgen receptor (AR) pathway-directed therapies [1, 3]. AR expression has been reported in neural areas, such as the prefrontal cortex and the mesocorticolimbic system, which are responsible for executive function [4, 5]. Cognitive impairments can lead to functional problems related to comprehension, concentration, and memory [6]. Thus, it is important that the impact of these AR-directed therapies on CNS-related AEs be identified and managed to ensure that patient safety and quality of life are maintained [1].
Anzeige
CNS-related AEs reported with AR inhibitors are thought to be associated with the penetration of the blood–brain barrier (BBB) by these drugs [7‐10]. The AR inhibitors enzalutamide and apalutamide penetrate the BBB with a brain:plasma ratio of 27% and 62%, respectively, in mice [7, 8]. In the phase III PROSPER trial of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), enzalutamide was associated with an increased risk of fatigue, falls, dizziness, headache, mental impairment disorders, and seizures compared with placebo [11]. A meta-analysis found a significantly higher risk of anxiety, insomnia, headache, and restless leg syndrome in patients with metastatic CRPC receiving enzalutamide versus those receiving placebo [12]. In the phase III SPARTAN trial of patients with nmCRPC, fatigue, falls, and mental impairment disorders were reported more frequently in patients receiving apalutamide plus ADT compared with placebo plus ADT, and seizures were reported in two patients treated with apalutamide [13].
Darolutamide is a highly potent oral AR inhibitor that is structurally distinct from enzalutamide and apalutamide [8]. Preclinical pharmacokinetic studies in male mice reported a very low BBB penetration of darolutamide with a brain:plasma ratio of 1.9–3.9% following oral doses of 25, 50, or 100 mg/kg twice daily for 7 days, which was markedly lower than that observed with enzalutamide and apalutamide [8]. In an autoradiography study in male rats, in vivo tissue distribution after a single dose each of 10 mg/kg 14C-labeled darolutamide, enzalutamide, or apalutamide revealed a tenfold lower brain:blood ratio of 14C-labeled darolutamide compared with the other two AR inhibitors (Fig. 1) [8, 14‐16]. In the phase III ARAMIS trial of patients with nmCRPC, the incidence of AEs was similar for darolutamide plus ADT and placebo plus ADT, including the CNS-related AEs of dizziness, impaired memory, cognitive disorders, and change in mental status [17, 18]. Fatigue was the only AE with an incidence > 10% in the darolutamide arm (13.2% vs. placebo, 8.3%). The incidence of AEs with darolutamide was generally lower than that reported with enzalutamide and apalutamide in the PROSPER and SPARTAN trials [11, 13, 18].
Fig. 1
Brain distribution of [14C]darolutamide, [14C]enzalutamide, and [14C]apalutamide at 8 h postdosing in male Wistar rats based on whole-body autoradiography [14]
×
The risk of drug-associated, CNS-related AEs is likely to be determined by the drug concentration in the brain after oral administration. This study investigated changes in cerebral blood flow (CBF) using arterial spin-labeled (ASL) magnetic resonance imaging (MRI) as a proxy for brain penetration of darolutamide, enzalutamide, and placebo. The ASL-MRI technique is a reliable and consistent measure of resting-state CBF that can be used to assess change in CBF related to brain function following administration of a single-dose drug [19‐22]. This technique has been applied to evaluation of CBF changes in individuals with mild cognitive impairment in response to memory-encoding tasks as a potential biomarker in Alzheimer disease [23].
2 Materials and Methods
2.1 Study Design
This phase I, randomized, placebo-controlled, three-period crossover study (NCT03704519) consisted of a screening visit, three treatment periods, and a follow-up visit for all participants (Fig. 2). The screening visit occurred within 35 days prior to the first treatment period and included screening MRI to assess for the presence of any structural variants or pathologic abnormalities. Each treatment period included a 1-day visit and a 42-day washout period, followed by a visit within 7 days from the end of the washout period after the third period. After completing the screening, participants were randomly assigned, using a computer-generated randomization list, to one of six different treatment sequences in which a single oral dose of darolutamide 300 mg (four tablets), enzalutamide 160 mg (four capsules), or placebo (four tablets) was administered approximately 30 min after a standardized meal on day 1. A lower dose of darolutamide than the approved treatment dose (600 mg) was used to achieve unbound plasma concentrations comparable with enzalutamide.
Fig. 2
Study design. Single doses of darolutamide 300 mg and enzalutamide 160 mg were administered. D/d day, DARO darolutamide, ENZA enzalutamide, MRI magnetic resonance imaging, P3 period 3, PBO placebo, PK pharmacokinetic
×
Anzeige
The study was conducted at a single study center in the UK (Center for Neuroimaging Sciences, Institute of Psychiatry, Psychology, and Neuroscience at King’s College Hospital, London). The protocol was reviewed and approved by the South Central—Berkshire Research Ethics Committee and the Medical and Healthcare Regulatory Authority before study initiation. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice, and met all local legal and regulatory requirements. All participants provided written informed consent.
2.2 Study Population
Participants were healthy males aged 18–45 years with a body mass index within the range of 18.0–30.0 kg/m2. Participants were excluded if they had known contraindication to MRI, structural variants or pathological abnormalities on screening period brain MRI, history of neurological or psychiatric disorders, ongoing medical condition involving the vital organs, diagnosed malignancy within 5 years, or had received any medication that may influence the study objectives within 2 weeks prior to the start of the study.
2.3 Study Procedures
ASL-MRI scans were performed on a GE Healthcare Discovery™ MR750 3 Tesla (T) scanner using a NOVA 32-channel head coil at 4 h (± 30 min) postdose in the afternoon on day 1 of each period. At each scanning visit, a three-plane localizer and a sagittal three-dimensional (3D) T1-weighted structural sequence covering the entire brain and skull were performed. Two ASL scans (about 6 min each) were acquired in the axial plane using a pseudocontinuous arterial spin-labeling sequence (pCASL) with a multishot, segmented 3D stack of axial spirals (eight arms) readout with a resultant spatial resolution of approximately 2 × 2 × 3 mm. The two ASL scans were averaged to increase signal-to-noise ratio. Labeling time was 1800 ms (a train of Hanning-shaped radiofrequency pulses) with an unbalanced labeling scheme. The post-labeling delay was 2025 ms and four inversion pulses were collected during the post-label delay. Images were obtained in an interleaved fashion, with fast spin echo (echo time of 11.1 ms), producing 512 readout points per interleave, with eight interleaves in total and four control-label pairs.
Prior to analysis, all CBF images for each participant/session were preprocessed using the standard unified segmentation-based pipeline in the Automatic Software for ASL Processing (ASAP) toolbox based on the statistical parametric mapping software (SPM version 12) run in Matlab 17b [24‐26]. The images were co-registered to the high-resolution T1-weighted structural image and then normalized to Montreal Neurological Institute (MNI) space via unified segmentation. In this process, the images were also upsampled to a resolution of 2 × 2 × 2 mm. Finally, the images were smoothed by an 8-mm smoothing kernel. One proton density image was collected at the end of the series for CBF quantification, which was performed in a blinded fashion following the current ASL consensus article [27]. To minimize bias due to variation in CBF in relation to the circadian rhythm effect, dosing of study drug occurred in the morning to allow the MRI scan to be consistently performed in the afternoon for each individual.
Blood samples were collected within approximately 15 min following the completion of the MRI scan in periods 1, 2, and 3 and on day 1 prior to study drug administration for periods 2 and 3. Plasma concentrations were measured for the individual diastereomers of darolutamide and enzalutamide as well as their major metabolites keto-darolutamide and N-desmethyl enzalutamide.
2.4 Outcome Measures
The primary endpoints were the whole-brain analyses of voxel-by-voxel changes in global grey matter CBF derived from ASL-MRI at 4 h (± 30 min) post-treatment for the comparisons of enzalutamide versus placebo, darolutamide versus placebo, and enzalutamide versus darolutamide. Secondary endpoints were changes in mean CBF in prespecified regions of interest (ROIs) relevant to cognitive function (i.e., the hippocampus, frontal cortex, and amygdala) as measured by ASL-MRI at 4 h (± 30 min) post-treatment for the same comparisons as the primary endpoint.
Safety was assessed by physical examination, reporting of AEs, vital signs, 12-lead electrocardiogram, and blood and urine assessments prior to each dose of study drug.
2.5 Statistical Methods
Statistical sample size estimation was not performed for this study. A published estimate of the power needed to detect a modest 10% change in perfusion in a placebo-controlled crossover design (i.e., size of change we observed in the striatum following haloperidol administration) showed that 12–18 participants would be sufficient to detect a significant change between visits [28]. The chosen sample size of 24 participants was planned to be equally assigned to the six treatment sequences. For primary endpoint analyses, paired t tests were performed to evaluate differences within each participant in each voxel of the whole-brain CBF maps (i.e., global grey matter) for the comparisons of enzalutamide versus placebo, darolutamide versus placebo, and enzalutamide versus darolutamide. This approach removes the influence of interparticipant variability. Results were only considered significant if they survived whole-brain family-wise error correction (< 0.05) based on the cluster size. Clusters were defined using an uncorrected cluster-forming threshold of p < 0.005. All analyses controlled for the potential confounding effects of drug-related changes in physiologic parameters (e.g., heart rate, systolic and diastolic blood pressure).
Anzeige
For secondary endpoint analyses, predefined ROI analyses were carried out using regions relevant to cognition, and mean CBF values were extracted using the MarsBar ROI toolbox in SPM12 [25, 29]. ROIs were constructed a priori using the neuroimaging meta-analysis repository, NeuroSynth. Linear mixed-effects models based on Matlab 2017b [26] were used with physiology as a nuisance covariate to compare the mean CBF in each region following study drug administration. These data underwent the same analysis as described above, and the results were considered significant with a critical alpha of 0.05 (p < 0.05).
The potential effects of treatment sequence were analyzed using an analysis of variance (ANOVA) including sequence, period, and treatment as fixed effects and subject (sequence) as a random effect. Point estimates (least squares means) and exploratory 90% confidence intervals (CIs) were calculated for the three comparisons in each ROI. A sequence effect was detected if the hypothesis of no sequence effect was rejected by the F test at an alpha significance level of 0.05.
3 Results
3.1 Participants
From October 2018 to October 2019, 26 healthy male subjects were randomized to receive study drug, and 23 subjects completed all three treatment periods and were included in the analysis (Fig. 3). Subjects had a median age of 25 years (range 19–44) and a median body mass index of 23.6 kg/m2 (range 18.4–30.4).
Fig. 3
Participant disposition. Protocol deviation: subject did not meet study entry criteria because he was participating in another clinical trial at the same time. AE: Subject had cough of moderate intensity 2 days after receiving placebo and withdrew from further dosing. Other: subject emigrated and was no longer able to attend study visits. A enzalutamide—placebo—darolutamide, AE adverse event, B darolutamide—enzalutamide—placebo, C placebo—darolutamide—enzalutamide, D darolutamide—placebo—enzalutamide, E enzalutamide—darolutamide—placebo, F placebo—enzalutamide—darolutamide
×
3.2 Pharmacokinetic Evaluation
Mean plasma concentrations of study drugs and metabolites were in the expected range, with geometric means of 941 ng/mL for darolutamide and 2679 ng/mL for enzalutamide at approximately 4 h postdosing (Table 1). Unbound drug concentration is considered more relevant for the ability to penetrate the BBB and was calculated for both compounds with correction for differences in their pharmacokinetic characteristics, including molecular weights, half-lives (darolutamide, 20 h; enzalutamide, 4 days) and protein binding (darolutamide, 92%; enzalutamide, 98%) [30, 31]. The respective unbound geometric mean concentrations were 189 nmol/L for darolutamide and 115 nmol/L for enzalutamide, which represent approximately 20% of the unbound concentration of both compounds observed at steady-state following administration of darolutamide 600 mg twice daily or enzalutamide 160 mg once daily (Fig. 4) [32]. There were no measurable predose concentrations of study drug at treatment periods 2 and 3, indicating complete washout of darolutamide and enzalutamide prior to the next study drug administration.
Table 1
Geometric mean (% coefficient of variation) of total pharmacokinetic concentrations of all analytes in plasma
Geometric mean (%CV) concentration at study times
Enzalutamide (ng/mL)
N-desmethyl enzalutamide (ng/mL)
Darolutamide (ng/mL)
(S,R)-darolutamide (ng/mL)
(S,S)-darolutamide (ng/mL)
Keto-darolutamide (ng/mL)
Post MRI (n = 24)
2679 (31%)
102 (60%)
941 (38%)
187 (45%)
745 (41%)
2076 (43%)
42 Days postdose [predose]a (n = 16)
< LLOQb
< LLOQb
< LLOQ
< LLOQ
< LLOQ
< LLOQ
CV coefficient of variation, LLOQ lower limit of quantification, MRI magnetic resonance imaging
aIn periods 2 and 3 on day 1 at predose, a pharmacokinetic sample was drawn to assess drug level at the end of the respective washout period; therefore, these values are assigned to the treatment of the previous period in this table
Fig. 4
Observed unbound plasma concentration of darolutamide and enzalutamide post-MRI (C4h unb). Single doses of darolutamide 300 mg and enzalutamide 160 mg were administered. Box: 25th to 75th percentile; horizontal line: median; χ: geometric mean; vertical lines extend from the box to a distance of at most 1.5 interquartile ranges and any value more extreme is plotted separately. C4h unb unbound plasma concentration at 4 h postdose, %Cav ss,unb unbound plasma concentration as a percentage of average steady-state concentration, MRI magnetic resonance imaging
×
Anzeige
3.3 Primary Endpoint
Whole-brain grey matter (i.e., global grey mean) showed a 3.5% reduction in CBF for enzalutamide compared with placebo and a 3.3% reduction in CBF for enzalutamide compared with darolutamide. There was no meaningful change in grey matter CBF for darolutamide versus placebo (0.1%). Whole-brain voxel-wise analysis found evidence in the temporo-occipital cortices of statistically significant localized reductions in CBF of 5.2% (cluster-wise pFWEcorr = 0.019; cluster extent of 4442 voxels) for enzalutamide compared with placebo, and 5.9% (cluster-wise pFWEcorr < 0.005, cluster extent of 6740 voxels) for enzalutamide versus darolutamide, but there was no significant CBF reduction for darolutamide compared with placebo (− 0.7%) (Fig. 5). Comparison of enzalutamide and darolutamide identified a significant reduction in temporo-occipital CBF, which extended into the right superior, middle, and inferior temporal gyrus, the right middle and inferior occipital gyrus, the temporo-occipital area, and the right angular gyrus/temporoparietal junction.
Fig. 5
Localized change in whole-brain grey matter cerebral blood flow in the temporo-occipital cortices. Data presented are mean ± standard error of the mean. Colored areas in three-dimensional brain figures indicate regions of significant difference in regional CBF between a pair of study interventions. These images are family-wise error-corrected statistical maps derived from all participants overlaid on an anatomic image. A cluster-forming threshold of p < 0.005 uncorrected was used. All measures were corrected for physiologic covariates (i.e., heart rate, systolic and diastolic blood pressure). CBF cerebral blood flow
×
3.4 Secondary Endpoints
Analysis of prespecified ROIs relevant to cognition showed consistent reductions in CBF with enzalutamide compared with darolutamide or placebo, but minimal changes for the comparison of darolutamide and placebo (Table 2). In the left dorsolateral prefrontal cortex, a significant reduction in CBF was observed for enzalutamide versus placebo (3.9%; p = 0.045) [Fig. 6]. In the right dorsolateral prefrontal cortex, a significant reduction was observed for enzalutamide versus darolutamide (4.4%; p = 0.037). Notable CBF changes that did not reach statistical significance included enzalutamide versus darolutamide in the left dorsolateral prefrontal cortex (− 2.9%) and enzalutamide versus placebo in the right dorsolateral prefrontal cortex (− 3.4%). Consistent reductions in localized CBF were observed for the left and right hippocampus, both anterior and whole, for enzalutamide compared with placebo and enzalutamide compared with darolutamide, but the differences did not reach statistical significance. Differences in CBF in the dorsolateral prefrontal cortex and hippocampus between darolutamide and placebo were negligible and not significant. After correction for multiple comparisons, no statistically significant differences were observed in any of the predefined ROIs, and no effects of treatment sequence were found in the ROIs.
Table 2
Cerebral blood flow in the global grey matter and predefined regions of interest by treatment and differences between treatments
Region
Darolutamide
Placebo
Enzalutamide
Placebo−darolutamide
Darolutamide−enzalutamide
Placebo−enzalutamide
mL/100 g/min
mL/100 g/min
mL/100 g/min
% Difference
% Difference
% Difference
Primary endpoints (whole-brain grey matter)
Global grey meana
55.4
55.5
53.5
− 0.14
− 3.32
− 3.46
Temporo-occipitala
68.1
67.6
64.0
0.73
− 5.91b
− 5.22b
Secondary endpoints (predefined regions)
Anterior cingulate
66.4
66.0
64.1
0.71
− 3.59
− 2.89
L amygdala
51.6
51.4
50.3
0.31
− 2.44
− 2.13
R amygdala
50.5
50.9
49.0
− 0.70
− 3.02
− 3.70c
L dorsolateral prefrontal cortex
56.0
56.5
54.3
− 0.99
− 2.92
− 3.87c
R dorsolateral prefrontal cortex
58.0
57.4
55.5
1.00
− 4.39c
− 3.43
Dorsomedial prefrontal cortex
57.2
57.1
55.5
0.21
− 2.90
− 2.70
L ventrolateral prefrontal cortex
64.1
64.3
62.5
− 0.31
− 2.38
− 2.68
R ventrolateral prefrontal cortex
61.0
60.8
59.0
0.29
− 3.28
− 2.99
Ventromedial prefrontal cortex
63.3
62.8
61.0
0.79
− 3.58
− 2.80
L anterior hippocampus
51.2
50.9
49.6
0.64
− 3.12
− 2.50
R anterior hippocampus
49.3
49.6
48.2
− 0.73
− 2.28
− 2.98
L whole hippocampus
51.2
50.9
49.6
0.57
− 3.04
− 2.49
R whole hippocampus
48.9
49.2
47.6
− 0.59
− 2.57
− 3.15
L parahippocampal gyrus
50.4
50.3
48.8
0.36
− 3.17
− 2.82
R parahippocampal gyrus
48.6
49.1
47.7
− 0.97
− 1.79
− 2.73
L ventral striatum
57.2
57.4
55.8
− 0.34
− 2.46
− 2.78
R ventral striatum
57.1
57.7
56.1
− 0.89
− 1.83
− 2.70
Negative percentage difference values indicate a reduction in CBF following drug administration (i.e., placebo > drug); positive values indicate drug-related increases (i.e., drug > placebo) in CBF
CBF cerebral blood flow, FWE family-wise error, L left, R right
aUsing voxel-based analysis of whole-brain grey matter
bStatistically significant (pFWE < 0.05)
cStatistically significant (p < 0.05 prior to Bonferroni correction for multiple comparisons)
Fig. 6
Region of interest analysis of cerebral blood flow changes in the left dorsolateral prefrontal cortex. Colored area in the 3D brain figure represents the brain area, which was prespecified from an atlas. Data presented are mean ± standard error of the mean CBF for the colored region depicted in the 3D brain figure for each treatment condition. aFor enzalutamide versus placebo, t(22) = 2.06; p = 0.045. 3D three-dimensional, CBF cerebral blood flow
×
3.5 Safety
The study drugs were well tolerated. Fifteen of 26 subjects (57.7%) experienced at least one AE of mild or moderate intensity, with 25.0%, 29.2%, and 28.0% of subjects experiencing AEs after receiving darolutamide, enzalutamide, and placebo, respectively. Eight AEs in six subjects (23.1%) were considered study drug-related and occurred in all three treatment groups: headache for darolutamide and enzalutamide, and headache and dizziness for placebo. One subject experienced an unrelated serious AE (cerebral infarction) that occurred after he had completed study drug administration for all three periods, and one subject experienced an unrelated AE (cough), which led to discontinuation of study drug. No clinically relevant changes in safety laboratory values, vital signs, or electrocardiogram parameters were observed at any time during the study.
4 Discussion
This is the first study using CBF, as assessed by ASL-MRI, as an indirect measure of brain penetration between ARIs, darolutamide and enzalutamide, and placebo. ASL-MRI is a noninvasive technique for assessing tissue perfusion by measuring blood flow. This technique identified greater central effects on brain physiology with enzalutamide relative to placebo and darolutamide. Significantly reduced CBF was observed with enzalutamide compared with darolutamide or placebo, while no meaningful difference in CBF was observed between darolutamide and placebo, indicating less penetration of darolutamide into the brain. These results are consistent with prior preclinical studies that showed a tenfold lower BBB penetration of darolutamide versus enzalutamide [8, 14‐16]. These data are also in line with the clinical safety profile of darolutamide, which shows similar incidence of CNS-related AEs between darolutamide and placebo in patients with nmCRPC [17, 18]. In the ARAMIS study, fatigue was reported in 13.2% of patients receiving darolutamide and 8.3% of those receiving placebo; rates of mental-impairment disorder (2.0% vs. 1.8%) and dizziness, including vertigo (4.5% vs. 4.0%), were minimally different between treatment groups [18].
Anzeige
CNS-related AEs are thought to be associated with the brain penetration of drugs [3, 7‐10]; therefore, these data suggest that darolutamide has low potential to cause CNS-related AEs that can impact a patient’s daily life. Significant reductions in CBF after enzalutamide treatment were localized, in part, to the temporo-occipital regions, which have several important cognitive and perceptual roles. For example, the superior temporal gyrus is integral to auditory processing [33], the temporoparietal junction is associated with the attentional network [34], and the angular gyrus is an integration hub, combining multisensory inputs for problem solving and attentional orientation [35]. Although causality is beyond the scope of this experiment, these functions are integral to daily life, and aberrant functioning arising from AR-directed therapy is not desirable. Several of the ROIs investigated in our study (hippocampus, amygdala) have been recently shown to have high AR-RNA expression using regional homogeneity and functional connectivity methods, highlighting increased interest in this area of study [36].
Altered CBF in the right amygdala and the dorsolateral prefrontal cortex after enzalutamide treatment is consistent with prior research, suggesting a role for androgen changes (via hypogonadism or gonadectomy) in reducing executive functioning and in the presence of mood disorders [5]. The dorsolateral prefrontal cortex is prominently involved in executive functioning, including the representation of task goals held in memory for the internal evaluation of one’s performance [37, 38] and control of cognitive processes for planning and reasoning [39]. Thus, the demonstration of altered CBF within this area has the potential to reduce oxygenation and impact executive functioning. In addition, decreased blood flow in the dorsolateral prefrontal cortex has been noted in depressed individuals, suggesting a negative impact on emotional regulation [40]. This finding is supported by a previous paper that identified higher scores on the Patient Health Questionnaire-9, a measure of depression, in individuals with metastatic CRPC treated with enzalutamide versus abiraterone [41].
The three-way crossover design of this study allowed intrasubject comparison of the effects of darolutamide and enzalutamide on brain perfusion, with the placebo providing a measure of amplitude of noise relative to the study drugs. The use of six treatment sequence groups avoided the potential bias of a fixed dosing sequence. However, the study was limited by a population that consisted of subjects who were younger than those who are traditionally affected with prostate cancer. An older population would be of interest as increasing age has been linked to greater BBB permeability [42]. The advantage of investigating all three treatments in a crossover design resulted in the limitation of single-dose administration for all treatments. With single-dose administration, the full exposure of enzalutamide and darolutamide, as observed during steady-state, could not be achieved in plasma. Administration, dose, and imaging time were selected to reach similar unbound concentrations of both compounds after single-dose administration, reflecting the relationship at steady-state. The unbound plasma concentrations at the time of the MRI scan were approximately 20% of the average steady-state concentrations for both compounds. The data indicate that the observed effect on CBF changes after single-dose administration may be even more pronounced when steady-state concentrations are reached. The impact of these changes in CBF on behavior and cognitive function after continuous treatment also warrants further investigation.
5 Conclusion
Enzalutamide significantly reduced CBF compared with both placebo and darolutamide, while darolutamide was not associated with significant reductions in localized CBF compared with placebo. These results support preclinical evidence showing low BBB penetration of darolutamide. Treatment-induced reduction in CBF may translate into changes in brain activity in areas, such as the frontal cortex, that may be relevant to cognitive function (e.g., executive function, memory, and anxiety). Further investigation in patients with prostate cancer is warranted.
Acknowledgements
The authors thank Dr. Hille Gieschen (Bayer Pharmaceuticals, Berlin, Germany) and colleagues for the images from the rat autoradiography study. Medical writing support was provided by Open Health Medical Communications (London, UK), supported by Bayer. Steven C. R. Williams wishes to thank the Wellcome Trust and the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London for their continued provision of facilities and support of our neuroimaging research.
Declarations
Funding
This work was supported by Bayer HealthCare.
Conflict of Interest
Steven C. R. Williams and Ndaba Mazibuko report research funding from Bayer, provided to the institution. Christian Zurth, Christian Kappeler, Iris Kuss, and Patricia E. Cole are employees of Bayer. Owen O’Daly and Fiona Patrick have no disclosures to declare.
Ethics Approval
This study was conducted at a single study center in the UK (Center for Neuroimaging Sciences, Institute of Psychiatry, Psychology, and Neuroscience at King’s College Hospital, London). The protocol was reviewed and approved by the South Central—Berkshire Research Ethics Committee and the Medical and Healthcare Regulatory Authority before study initiation. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice, and met all local legal and regulatory requirements. All participants provided written informed consent.
Consent to Participate
Written informed consent was obtained from all individual participants in the study.
Consent for Publication
All authors reviewed and approved the manuscript submitted for publication and are responsible for the correctness of the statements provided in the manuscript.
Data Availability
Availability of the data underlying this publication will be determined according to Bayer’s commitment to the EFPIA/PhRMA ‘Principles for responsible clinical trial data sharing’. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing, upon request from qualified scientific and medical researchers, patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the United States (US) and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after 1 January 2014. Interested researchers can use https://www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal. Data access to anonymized patient-level data, protocols and clinical study reports will be granted after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel, and will take all necessary measures to ensure that patient privacy is safeguarded.
Code Availability
Not applicable.
Author Contributions
Conceptualization: SCRW, IK, PEC. Methodology: SCRW, OO’D, CZ, FP, CK, PEC. Formal analysis and investigation: SCRW, NM, OO’D, CZ, FP, PEC. Writing – original draft preparation: SCRW, OO’D, FP. Writing – review and editing: SCRW, NM, OO’D, CZ, FP, CK, IK, PEC. Funding acquisition: SCRW. Resources: SCRW. Supervision: SCRW, NM. All authors participated in the critical review and revision of this manuscript and provided approval of the manuscript for submission.
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial
verfasst von
Steven C. R. Williams Ndaba Mazibuko Owen O’Daly Christian Zurth Fiona Patrick Christian Kappeler Iris Kuss Patricia E. Cole
Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.
Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.
Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.
„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
